Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss.

Journal Article (Clinical Trial;Journal Article;Multicenter Study)

BACKGROUND: Androgenetic alopecia is a common condition of adult men. Finasteride, a type 2 5alpha-reductase inhibitor, decreases the formation of dihydrotestosterone from testosterone. OBJECTIVE: Two separate clinical studies were conducted to establish the optimal dose of finasteride in men with this condition. METHODS: Men from 18 to 36 years of age with moderate vertex male pattern hair loss received finasteride 5, 1, 0.2, or 0.01 mg/day or placebo based on random assignment. Efficacy was determined by scalp hair counts, patient self-assessment, investigator assessment, and assessment of clinical photographs. Safety was assessed by clinical and laboratory measurements and by analysis of adverse experiences. RESULTS: Efficacy was demonstrated for all end points for finasteride at doses of 0.2 mg/day or higher, with 1 and 5 mg demonstrating similar efficacy that was superior to lower doses. Efficacy of the 0.01 mg dose was similar to placebo. No significant safety issues were identified in the trials. CONCLUSION: Finasteride 1 mg/day is the optimal dose for the treatment of men with male pattern hair loss and was subsequently identified for further clinical development.

Full Text

Duke Authors

Cited Authors

  • Roberts, JL; Fiedler, V; Imperato-McGinley, J; Whiting, D; Olsen, E; Shupack, J; Stough, D; DeVillez, R; Rietschel, R; Savin, R; Bergfeld, W; Swinehart, J; Funicella, T; Hordinsky, M; Lowe, N; Katz, I; Lucky, A; Drake, L; Price, VH; Weiss, D; Whitmore, E; Millikan, L; Muller, S; Gencheff, C

Published Date

  • October 1999

Published In

Volume / Issue

  • 41 / 4

Start / End Page

  • 555 - 563

PubMed ID

  • 10495375

Pubmed Central ID

  • 10495375

International Standard Serial Number (ISSN)

  • 0190-9622


  • eng

Conference Location

  • United States